How was cognitive behavioural therapy for mood disorder implemented in Japan? A retrospective observational study using the nationwide claims database from FY2010 to FY2015.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
05 05 2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 16 2 2021
Statut: epublish

Résumé

To clarify the dissemination status of cognitive behavioural therapy (CBT) in Japan under the national health insurance scheme. Retrospective observational study. National Database of Health Insurance Claims and Specific Health Checkups of Japan. Patients who received CBT under the national health insurance scheme from fiscal years (FY) 2010 to 2015. We estimated the change rate and the standardised claim ratio (SCR) for the number of patients receiving CBT and analysed the association between the CBT status and several regional factors. We found that (a) a total of 60 304 patients received CBT during the study period; (b) the number of patients receiving CBT was highest in the first year (-1.8% from FY2010 to FY2015); (c) the number of patients who received CBT per 100 000 population decreased (or remained at zero) in most prefectures (32 out of 47); (d) there was a maximum 424.7-fold difference between prefectures in the standardised claim ratio for CBT and (e) the number of registered CBT institutions was significantly associated with the number of patients who received CBT. The provision of CBT did not increase in the first 6 years (FY2010-2015) after its coverage in Japan's national health insurance scheme. Further studies including a questionnaire survey of registered CBT institutions are required to get more detailed information on the dissemination of CBT in Japan.

Identifiants

pubmed: 32376747
pii: bmjopen-2019-033365
doi: 10.1136/bmjopen-2019-033365
pmc: PMC7223011
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e033365

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: NY has received a speaking honorarium from Gakken Medical Support, and writing honoraria from Igaku Shoin, Nihon-Hyouronsha, Sogensha, and Medical Friend. The other authors declare that they have no conflicts of interest.

Références

Lancet. 2013 Feb 2;381(9864):375-84
pubmed: 23219570
Psychiatry Clin Neurosci. 2011 Mar;65(2):121-9
pubmed: 21414087
PLoS One. 2015 Oct 27;10(10):e0140704
pubmed: 26506554
J Clin Psychiatry. 2013 Jun;74(6):595-602
pubmed: 23842011
J Clin Psychol. 2009 Jan;65(1):36-52
pubmed: 19051275
Psychother Psychosom. 2019;88(4):244-246
pubmed: 31121592
Annu Rev Clin Psychol. 2018 May 7;14:159-183
pubmed: 29350997
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
Clin Psychol Rev. 2006 Jan;26(1):17-31
pubmed: 16199119
Behav Res Ther. 2009 Nov;47(11):910-20
pubmed: 19647230
Behav Res Ther. 2009 Nov;47(11):902-9
pubmed: 19664756
Can J Psychiatry. 2016 Sep;61(9):524-39
pubmed: 27486150
Can J Psychiatry. 2013 Jul;58(7):376-85
pubmed: 23870719
Neuropsychiatr Dis Treat. 2018 Oct 09;14:2633-2641
pubmed: 30349261
Seishin Shinkeigaku Zasshi. 2012;114(6):690-5
pubmed: 22844820
Psychiatry Clin Neurosci. 2015 Sep;69(9):553-62
pubmed: 25601043
Drug Alcohol Depend. 2016 Jan 1;158:118-25
pubmed: 26652896
Aust N Z J Psychiatry. 2014 Nov;48(11):977-1008
pubmed: 25351912
Biol Pharm Bull. 2015;38(1):53-7
pubmed: 25744458
Aust N Z J Psychiatry. 2009 Jun;43(6):539-47
pubmed: 19440886
Clin Psychol Rev. 2010 Mar;30(2):194-202
pubmed: 19942331
J Clin Psychiatry. 2017 Sep/Oct;78(8):1126-1135
pubmed: 28252882
Int J Epidemiol. 2014 Apr;43(2):476-93
pubmed: 24648481
Environ Health Prev Med. 2017 Jun 6;22(1):51
pubmed: 29165139
BMC Res Notes. 2010 Jun 07;3:160
pubmed: 20529252
J Gen Intern Med. 2000 Aug;15(8):527-34
pubmed: 10940143
J Affect Disord. 2018 Dec 1;241:554-562
pubmed: 30153639

Auteurs

Yuta Hayashi (Y)

Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
Department of Nursing, Graduate School of Health Sciences, Kobe University, Kobe, Japan.

Naoki Yoshinaga (N)

School of Nursing, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan naoki-y@med.miyazaki-u.ac.jp.

Yosuke Sasaki (Y)

Department of Animal and Grassland Sciences, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Center for Animal Disease Control, University of Miyazaki, Miyazaki, Japan.

Hiroki Tanoue (H)

Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
School of Nursing, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Kensuke Yoshimura (K)

Center for Next Generation of Community Health, Chiba University Hospital, Chiba, Japan.

Yuko Kadowaki (Y)

Division of Biostatistics, Kurume University School of Medicine, Kurume, Japan.

Yasuji Arimura (Y)

Clinical Research Support Center, University of Miyazaki Hospital, Miyazaki, Japan.

Toshihiko Yanagita (T)

School of Nursing, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Clinical Research Support Center, University of Miyazaki Hospital, Miyazaki, Japan.

Yasushi Ishida (Y)

Division of Psychiatry, Department of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH